

Remarks

Applicants elect group IX, claims 3-7 and 10-11, drawn to an isolated nucleic acid encoding SEQ ID NO: 18, including SEQ ID NO: 17 (mannosidase 1C), with traverse.

Claims 1-19 were pending. Due to the restriction requirement, claims 1-2, 8-9, and 12-19 are cancelled and claim 11 was amended without prejudice to prosecution in another application. Claim 3 was amended due to the cancellation of claim 1. Claims 20-30 are added. Therefore, claims 3-7, 10-11, and 20-30 are now pending.

Support for the new claims can be found throughout the specification, for example:

Claims 20-23: page 4, lines 19-22;

Claims 24-27: page 7, lines 19-23

Claim 28: page 12, lines 4-16; and

Claims 29-30: page 7, lines 14-17.


The specification was amended to correct obvious typographical spelling errors.

No new matter is added by this amendment.

If the Examiner has any questions regarding the present response, he is invited to telephone the undersigned.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446